<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGS" rel="nofollow">WGS</a>) during the period from April 16, 2025 through May 4, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. <a href="https://www.globenewswire.com/Tracker?data=WwtMwJacOXFy8Dr4AYBjv5U3LFkXAkwl2reCEQTvdCnFLPQsTuYml-dxPT4X-6yiuxCcAOP41eh3i-3NNYQwwIfUjxZOVRQeC1qCOX3GlQiBySQpUNLhwZJQm2a8O7SXMr2dSa1wLnIUjNHr3oxqPww3Wq6EU-MU-ku4WFzH6srL7AkS6IAv6BvNwPdvW840dkCwPsKIVatykBTbFf9ynmL9LzQzdrmGCl6WZNB2XEM=" rel="nofollow" target="_blank" rel="nofollow"><u>Request an institutional investor loss assessment</u></a>. You may also contact Joseph E. Levi, Esq. at <a href="https://www.globenewswire.com/Tracker?data=0a9aUCBdMxQXqbpQNQwPEIG4JXqoBRj135Ur3X2f3GyWhayXB88FVjeBXh758nMbdFlzL5FH86JmylTx-Lq1dj83lEpOq3HkbUC5y0COomM=" rel="nofollow" target="_blank" rel="nofollow"><u> [email protected] </u></a> or (212) 363-7500.</p> <p>WGS shares declined $33.42 per share, or 49.20%, closing at $34.51 after the Company disclosed a $31.2 million impairment charge, slashed full-year revenue guidance by approximately $65 million, and revealed that a recent acquisition had failed to deliver promised value. The window to apply for lead plaintiff closes on August 3, 2026.</p> <p><strong>Notice to Institutional Holders</strong></p> <p>Pension funds, mutual funds, endowments, and other institutional holders of WGS common stock face distinct considerations when a securities class action is filed. With over 29.69 million shares outstanding, institutional holders likely represented a significant portion of the float during the Class Period. Portfolios that acquired shares at prices approaching the Class Period high of $167.52 face potential per-position losses that may trigger fiduciary review obligations under governing plan documents and applicable regulations.</p> <p><strong>ERISA and Fiduciary Considerations</strong></p> <p>For ERISA-governed plans that held WGS in participant-directed accounts or managed portfolios, the corrective disclosure on May 4, 2026 may require affirmative evaluation of recovery options.</p> <ul type="disc"> <li style="margin-top:2pt; margin-bottom:2pt;">Plan fiduciaries have an obligation to investigate potential claims that could benefit plan participants and beneficiaries</li> <li style="margin-top:2pt; margin-bottom:2pt;">The lead plaintiff role provides institutional investors with direct oversight of litigation strategy, settlement terms, and counsel selection</li> <li style="margin-top:2pt; margin-bottom:2pt;">Serving as lead plaintiff involves no out-of-pocket cost; counsel is compensated from any recovery approved by the Court</li> <li style="margin-top:2pt; margin-bottom:2pt;">Institutional investors with the ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/26/06/g53209908/wgs-shareholder-alert-genedx-holdings-corp-securities-class-action-lawsuit-investors-with-losses-m?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky>Full story available on Benzinga.com</a></p>
WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
